Photo by nci from unsplash
Drugs that target KRAS 12C covalently, AMG 510 and MRTX849, are now in the clinic. Recent papers describe development of these compounds, their selectivity and properties, early clinical data, and… Click to show full abstract
Drugs that target KRAS 12C covalently, AMG 510 and MRTX849, are now in the clinic. Recent papers describe development of these compounds, their selectivity and properties, early clinical data, and potential combination therapies. These papers herald a new era in Ras research, with improved drugs and strategies certain to follow.
Keywords:
sticking kras;
covalent inhibitors;
inhibitors enter;
enter clinic;
kras covalent
Journal Title: Cancer cell
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer cell
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!